Many innovative digital technologies are promising in supporting medication adherence and clinical decision making. However, they come with certain costs. Whether these costs are offset by clinical and economic benefits is often unknown. To uncover the economic case for digital inhalers, MAECON has performed a cost-effectiveness analysis in patients with difficult-to-treat asthma. Various scenarios looked at the long-term costs and benefits as well as the overall incremental cost-effectiveness ratio (ICER). In this case, digital inhalers seem cost-effective by enhancing medication adherence and inhaler technique and reducing the required number of add-on biologics.
